Lars Holtug sold $62k of ASND
director at Ascendis Pharma A/S. 236 shares at an average of $264.13, traded Sep 2, 2026, filed Sep 3, 2026.
Score components
- +15RoleDirector
- +7Trade size$62k at market
- 0Share of holdings soldSold 5.6% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-26-000395, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | SOpen-market sale Ordinary Shares | -236 | $264.13 | $62k | 4,000 | 39 d ago |
Related signals
Other insiders at Ascendis Pharma A/S and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Ascendis Pharma A/S | Mads Bodenhoff SVP & PAO | $811k 3,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.